Microangiopathic Hemolytic Anemia Research This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Recent advances in the management of immune-mediated thrombotic thrombocytopenic purpura
Blood Res. 2022 Apr 30;57(S1):37-43. doi: 10.5045/br.2022.2022005.ABSTRACTImmune-mediated thrombotic thrombocytopenic purpura (iTTP) is a potentially life-threatening thrombotic microangiopathy caused by autoantibody-mediated severe ADAMTS13 deficiency. TTP should be suspected in patients with microangiopathic hemolytic anemia and thrombocytopenia without a definite cause. Early detection of iTTP and prompt treatment with plasma exchange and corticosteroids are essential. Rituximab administration should be considered for refractory or relapsed iTTP, and can be used as a first-line adjuvant or preemptive therapy. Treatment ...
Source: Blood Research - April 28, 2022 Category: Hematology Authors: Sung Hwa Bae Sung-Hyun Kim Soo-Mee Bang Source Type: research

TA-TMA risk stratification: is there a window of opportunity to improve outcomes?
Transplant-associated thrombotic microangiopathy (TA-TMA) is a clinical syndrome of endothelial injury resulting in microangiopathic hemolytic anemia, consumptive thrombocytopenia and microvascular thrombosis which cause organ and tissue ischemia. Multiple insults after hematopoietic stem cell transplant (HSCT) can trigger TA-TMA in susceptible individuals.1,2 These insults include medications, infections, and dysimmunity, among others. TA-TMA can range from a mild, self-limiting disease to a life-threatening multi-organ injury syndrome (MODS). (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - April 28, 2022 Category: Hematology Authors: Sonata Jodele, Christopher E Dandoy, Anthony Sabulski, Jane Koo, Adam Lane, Kasiani C Myers, Gregory Wallace, Ranjit S Chima, Ashley Teusink-Cross, Russel Hirsch, Thomas D Ryan, Stefanie Benoit, Stella M Davies Source Type: research

Transplantation-Associated Thrombotic Microangiopathy Risk Stratification: Is There a Window of Opportunity to Improve Outcomes?
Transplantation-associated thrombotic microangiopathy (TA-TMA) is a clinical syndrome of endothelial injury resulting in microangiopathic hemolytic anemia, consumptive thrombocytopenia, and microvascular thrombosis, which cause organ and tissue ischemia. Multiple insults after hematopoietic stem cell transplantation (HSCT) can trigger TA-TMA in susceptible individuals [1,2]; these insults include medications, infections, and dysimmunity, among others. TA-TMA can range from a mild, self-limiting disease to a life-threatening multiorgan injury syndrome (MODS) [3 –7]. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - April 28, 2022 Category: Hematology Authors: Sonata Jodele, Christopher E. Dandoy, Anthony Sabulski, Jane Koo, Adam Lane, Kasiani C. Myers, Gregory Wallace, Ranjit S. Chima, Ashley Teusink-Cross, Russel Hirsch, Thomas D. Ryan, Stefanie Benoit, Stella M. Davies Source Type: research

Slow It Down: A Case Report Of Microangiopathic Hemolytic Anemia In A Heartmate III Patient
We present a case of microangiopathic hemolytic anemia (MAHA), not related to pump thrombosis in a recent implanted HM3 LVAD patient which resolved by decreasing LVAD speed. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - April 1, 2022 Category: Cardiology Authors: Ariane T. Lemieux, Arpan Patel, Timothy Gong, William Sovic, Barry Cooper, Cesar Guerrero-Miranda Tags: 331 Source Type: research